RGPX · As filed with the SEC
Regenerex Pharma cash flow statement, by fiscal year
The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
STATEMENTS OF CASH FLOWS · USD
| USD | FY2024 Year ended Mar 31, 2025 | FY2023 Year ended Mar 31, 2024 | FY2023 Year ended Mar 31, 2023 | FY2022 Year ended Mar 31, 2022 | FY2020 Year ended Mar 31, 2021 | FY2019 Year ended Mar 31, 2020 | FY2018 Year ended Mar 31, 2019 | FY2017 Year ended Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Net loss | — | — | — | — | (353,752) | (111,589) | (93,579) | (49,671) |
| Net Income | (2,527,041) | (3,543,827) | (137,330) | (195,591) | — | — | — | — |
| Loss on discontinued operations | — | — | — | 5,510 | — | — | — | — |
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||||||
| Restructuring Expense | — | — | — | — | 245,563 | — | — | — |
| Depreciation Expense | 3,054 | 4,278 | 3,420 | 3,529 | 4,661 | 6,991 | 5,334 | 2,659 |
| Effect of Exchange Rate on Cash | — | — | — | 4,751 | 4,616 | 7,632 | — | — |
| Foreign currency adjustments | (5,728) | (2,636) | (25,629) | — | — | — | — | — |
| Stock-Based Compensation Expense | 132,662 | 211,698 | — | 45,000 | — | — | 45,000 | 10,250 |
| Research and Development Expense | — | 2,400,000 | — | — | — | — | — | — |
| Non-cash interest related to Note extension | 240,000 | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | 19,807 | 53,719 | — | — | — | — | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Inventories | — | — | — | — | 1,128 | (246,691) | — | — |
| Prepaid expenses | 2,190 | (2,540) | 5,256 | (4,043) | (1,213) | 9,070 | (9,070) | — |
| Change in Accounts Payable | — | — | 78,119 | 76,432 | 36,345 | 43,408 | 5,256 | 640 |
| Net Cash from Operating Activities | — | — | (76,164) | (64,412) | — | — | — | — |
| Net Cash from Operating Activities | — | — | — | (5,510) | — | — | — | — |
| Accounts payable | 187,915 | 159,641 | — | — | — | — | — | — |
| Accrued compensation | 330,773 | 290,655 | — | — | — | — | — | — |
| Other accrued liabilities | (8,983) | (28,536) | — | — | — | — | — | — |
| Net Cash from Operating Activities | (1,625,351) | (457,548) | (76,164) | (69,922) | (62,652) | (291,179) | (47,059) | (36,122) |
| Website development | — | — | — | (8,600) | — | (6,000) | — | (16,000) |
| Computer equipment | — | — | (1,398) | — | — | — | — | — |
| Purchase of furniture and computer equipment | (1,228) | (6,299) | — | — | — | — | — | — |
| Net Cash from Investing Activities | (1,228) | (6,299) | (1,398) | (8,600) | — | (6,000) | — | (16,000) |
| Cash Flows from Financing Activities: | ||||||||
| Related-party advances | — | — | — | — | — | 2 | 63,877 | 53,850 |
| Related party advances | — | — | 200 | — | — | — | — | — |
| Proceeds from Debt Issuance | — | — | 37,857 | 73,565 | 64,094 | 214,091 | 70,000 | — |
| Proceeds from Debt Issuance | 9,962 | 3,490 | 40,500 | 695 | — | — | — | — |
| Net Cash from Financing Activities | — | (10,000) | — | — | — | — | — | — |
| Other Affiliates | — | 3,844 | — | — | — | — | — | — |
| Affiliated Entity | 284,460 | 120,000 | — | — | — | — | — | — |
| Payments of notes payable to shareholders | (201,562) | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | (113,628) | (47,500) | (2,500) | — | — | — | — | — |
| Proceeds from Stock Issuance | 2,300,000 | 393,250 | — | — | — | — | — | — |
| Net cash provided by financing activities | 2,279,232 | 463,084 | 76,057 | 74,260 | 64,094 | 214,093 | 133,877 | 53,850 |
| Net Change in Cash | — | — | — | — | 1,442 | (83,086) | 86,818 | 1,728 |
| Net Change in Cash | 652,653 | (763) | (1,505) | (4,262) | — | — | — | — |
| Cash and cash equivalents, beginning of year | — | — | 2,640 | 6,902 | 5,460 | 88,546 | 1,728 | — |
| Cash and cash equivalents, end of year | — | — | — | 2,640 | 6,902 | 5,460 | 88,546 | 1,728 |
| Cash and cash equivalents, beginning of year | 372 | 1,135 | 2,640 | — | — | — | — | — |
| Cash and cash equivalents, end of year | 653,025 | 372 | 1,135 | — | — | — | — | — |
| Accrued interest converted into note payable to shareholder | — | — | — | 42,818 | — | — | — | — |
| Interest Expense | 27,568 | — | — | — | — | — | — | — |
| Accrued interest converted into note payable to shareholder | — | — | — | — | 13,838 | — | — | — |
| Accrued interest converted into notes payable to shareholder | 82,232 | 66,469 | 30,294 | — | — | — | — | — |
| Net Cash from Operating Activities | — | — | — | 150,000 | — | — | — | — |
| Accrued interest converted into note payable | — | 52,545 | — | — | — | — | — | — |
| Accrued interest converted into notes payable to related parties | 24,771 | — | — | — | — | — | — | — |
| Operating lease, ROU asset and liabilities | 52,203 | 953,355 | — | — | — | — | — | — |
| Note payable issued for research and development | — | 2,400,000 | — | — | — | — | — | — |
| Note payable issued for Note extension | 240,000 | — | — | — | — | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.